Abstract
Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bast RC, Feeny M, Lazarus H, Nadler LM, Colvin RB and Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331–1337
Bast RC, Klug TL, John ES and Al E (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883–887
Blessing JA (1990) Design, analysis, and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G (ed) Chemotherapy of Gynecologic Cancer, 2nd edn., Wiley-Liss: New York, pp. 63–97
Bridgewater JA, Nelstrop AE, Rustin GJS, Gore ME, McGuire WP and Hoskins WJ (1999) Comparison of standard and CA125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 17: 501–508
Buller RE, Berman ML, Bloss JD, Manetta A and DiSaia PJ (1992) Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecologic Oncology 47: 87–92
Davelaar EM, Bonfrer JMG, Verstraeten RA, ten Bokkel Huinink WW and Kenenmans P (1996) CA125 A valid marker in ovarian carcinoma patients treated with paclitaxel. Cancer 78: 118–127
Department of Health (1999) Improving outcomes in gynaecological cancers, DoH: London
Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC and Zurawski VR (1992) Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 80: 14–18
Eisenhauer EA, Vermorken JB and van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 8: 963–968
Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RCF, Wilkinson P, Cruickshank D, McAllister EJ, Redman CWE, Parker D, Scott IV, Slevin ML and Roulston JE (1993) The prognostic value of serum CA125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 3: 285–292
Gadducci A, Baichhi U, Marrai R, Ferdegini M, Bianchi R and Facchini V (1996) Preoperative evaluation of D-dimer and CA125 levels in differentiating benign from malignant ovarian masses. Gynecologic Oncology 60: 197–202
Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J and Oram D (1988) Multimodal approach to screening for ovarian cancer. Lancet, 268–271
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C and Grudzinskas J (1990) A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97: 922–929
Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinkas JG and Oram D (1993) Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ 306: 1030–1032
Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AJ, Sibley K, Lowe DG and Oram DH (1999) Screening for ovarian cancer: a pilot randomised study. Lancet 353: 1207–1210
Krebs H, Goplerud DR, Kilpatrick SJ, Myers MB and Hunt A (1986) Role of CA125 as tumour marker in ovarian carcinoma. Obstet Gynecol 67: 473–477
Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC and Bast RC (1987) CA125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69: 223–227
Markman M (1993) A proposal to use CA125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecologic Oncology 51: 297–298
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Nagele F, Petru E, Medl M, Kainz C, Graf AH and Sevelda P (1995) Preoperative CA125: an independent prognostic factor in patients with Stage I epithelial ovarian cancer. Obstet Gynecol 86: 259–264
Ng LW, Homesley HD, Barrett RJ, Welander CE and Case LD (1989) CA125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. Am J Clin Oncol 12: 106–109
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655
Pearl ML, Yashar CM, Johnstone CM, Reynolds RK and Roberts MD (1994) Exponential regression of CA125 during salvage treatment of ovarian cancer with Taxol. Gynecologic Oncology 53: 339–343
Rustin GJ, Nelstrop A, Stilwell J and Lambert HE (1992) Savings obtained by CA125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer 28: 79–82
Rustin GJ, van der Burg ME and Berek JS (1993) Advanced ovarian cancer. Tumour markers. Ann Oncol 4(Suppl 4): 71–7
Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H and Lambert HE (1996 a) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 14: 1545–1551
Rustin GJ, Nelstrop AE, Tuxen MK and Lambert HE (1996 b) Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study. Ann Oncol 7: 361–36
Rustin GJS, Nelstrop AE, Bentzen SM, Piccart MJ and Bertelsen K (1999) Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 10: S21–S27
Rustin G, Nelstrop A, Bentzen S, Bond S and McClean P (2000) Selection of active drugs for ovarian carcinoma based on CA125 and standard response rates in phase II trials. J Clin Oncol (in press)
Seir CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N and Blasi F (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58: 1843–1849
Sevelda P, Schemper M and Spona J (1989) CA125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 161: 1213–1216
Skates SJ, Xu F, Yu Y, Sjovall K, Einhorn N, Chang Y, Bast RC and Knapp RC (1995) Toward an optimal algorithm for ovarian cancer screening with longitudinal tumour markers. Cancer 76: 2004–2010
Tuxen MK, Soletormos G and Dombernowsky P (1995) Tumour markers in the management of patients with ovarian cancer. Cancer Treat Rev 21: 215–245
van der Burg MEL, Lammes FB, van Putten WLJ and Stoter G (1988) Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecologic Oncology 30: 307–312
van der Burg MEL, Lammes FB and Verweij J (1990) The role of CA125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1: 301–302
Ward BW (1994) Tumour markers in ovarian cancer: the current state of clinical use. Klinisches Labor 40: 1227–1231
Woolas RP, Xu FJ, Jacobs IJ, YH Y, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH and Bast RCJ (1993) Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85: 1748–1751
Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O’Briant K, Berchuck A and Soper JT (1995) Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecologic Oncology 59: 111–116
Xu F-J, Yu Y-H, Daly L, DeSombre K, Anselmino L, Hass GH, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C, Layfield LJ and Bast RCJ (1993) OVX1 radioimmunoassa complements CA125 for predicting the presence of residual ovarian carcinoma at second look surgical surveillance procedures. J Clin Oncol 11: 1506–1510
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Meyer, T., Rustin, G. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82, 1535–1538 (2000). https://doi.org/10.1054/bjoc.2000.1174
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1174
This article is cited by
-
Optimisation of Cytoreductive Surgery in Relation to Ca 125 in Epithelial Ovarian Cancer
Indian Journal of Gynecologic Oncology (2018)
-
Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma
Archives of Gynecology and Obstetrics (2018)
-
Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer
Scientific Reports (2017)
-
Clinical significance of serum CA125 in diffuse malignant mesothelioma
SpringerPlus (2016)
-
Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin
World Journal of Surgical Oncology (2016)